These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 288743)
1. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. Cadman E; Eiferman F J Clin Invest; 1979 Sep; 64(3):788-97. PubMed ID: 288743 [TBL] [Abstract][Full Text] [Related]
2. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells. Roberts D; Peck C; Hilliard S; Wingo W Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642 [TBL] [Abstract][Full Text] [Related]
3. Effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells. Roberts D; Peck C Cancer Res; 1981 Feb; 41(2):505-10. PubMed ID: 7448798 [TBL] [Abstract][Full Text] [Related]
4. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside. Tanaka M; Kimura K; Yoshida S Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450 [TBL] [Abstract][Full Text] [Related]
5. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity. Rauscher F; Cadman E Cancer Res; 1983 Jun; 43(6):2688-93. PubMed ID: 6189585 [TBL] [Abstract][Full Text] [Related]
6. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in L1210 cells by fluoropyrimidine pretreatment. Grant S; Cadman E Cancer Res; 1982 Sep; 42(9):3550-6. PubMed ID: 6213294 [TBL] [Abstract][Full Text] [Related]
7. [The effect of methotrexate on intracellular nucleotide pools]. Kawasaki H; Okubo T; Shimizu N; Komada M; Sako T; Hirota H; Noboru T; Kamiya H; Sakurai M; Izawa T Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):485-92. PubMed ID: 4039917 [TBL] [Abstract][Full Text] [Related]
8. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of 1-beta-D-arabinofuranosylcytosine accumulation within L1210 cells and increased cytotoxicity following thymidine exposure. Grant S; Lehman C; Cadman E Cancer Res; 1980 May; 40(5):1525-31. PubMed ID: 7370990 [No Abstract] [Full Text] [Related]
10. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate. Edelstein M; Vietti T; Valeriote F Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C). Riva CM; Rustum YM; Preisler HD Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925 [No Abstract] [Full Text] [Related]
12. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response. Riva CM; Rustum YM Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596 [TBL] [Abstract][Full Text] [Related]
13. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60. Grant S; Bhalla K; Rauscher F; Cadman E Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943 [TBL] [Abstract][Full Text] [Related]
14. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system. Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859 [TBL] [Abstract][Full Text] [Related]
15. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Plunkett W; Hug V; Keating MJ; Chubb S Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239 [TBL] [Abstract][Full Text] [Related]
16. Enhanced production of intracellular ara-CTP after sequential use of methotrexate and 1-beta-D-arabinofuranosylcytosine. Nobori T; Okubo T; Shimizu N; Kawasaki H; Sako T; Komada M; Hirota H; Kamiya H; Sakurai M Leuk Res; 1985; 9(10):1263-5. PubMed ID: 4068748 [TBL] [Abstract][Full Text] [Related]
17. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells. Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533 [TBL] [Abstract][Full Text] [Related]
18. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines. Kees UR; Ford J; Dawson VM; Piall E; Aherne GW Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661 [TBL] [Abstract][Full Text] [Related]
19. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Gandhi V; Estey E; Du M; Keating MJ; Plunkett W Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841 [TBL] [Abstract][Full Text] [Related]
20. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia. Colly LP; Peters WG; Willemze R Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]